The biosimilar Hyrimoz showed similar flare rates to Humira, but 25% of patients experienced adverse events, mainly injection site reactions. Injection pain, linked to Hyrimoz's citrate content and ...

(RTTNews) - Sandoz said that the citrate-free high-concentration formulation or HCF of its biosimilar Hyrimoz (adalimumab-adaz) injection will be available in the United States starting July 1.

Sandoz has obtained the Food and Drug Administration’s blessing for a citrate-free high-concentration formulation of its biosimilar Hyrimoz (adalimumab-adaz) injection. The adalimumab citrate-free HCF ...

FDA approval of generic pharmaceutical maker Sandoz’s Hyrimoz injection, a biosimilar for Humira, has the potential to “to expand access for millions,” according to a March 21 news release. The ...

Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab). Sandoz ...

The US Food and Drug Administration has approved a citrate-free, 100 mg/mL formulation of the biosimilar adalimumab-adaz (Hyrimoz), according to a statement from manufacturer Sandoz. Sandoz said that ...

Please provide your email address to receive an email when new articles are posted on . The researchers added that, “subsequently, [biosimilar adalimumab] effectiveness and safety were proved in two ...

As widely expected by the pharmaceutical industry, seven pharmaceutical companies are releasing biosimilars of AbbVie's Humira. Boehringer Ingelheim's Cyltezo (adalimumab-adbm), an interchangeable ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the third biosimilar to adalimumab, adalimumab-adaz, for all eligible indications of the ...

FILE - Packaging for AbbVie's drug, Humira. Patients who take the autoimmune disease treatment can get some price relief when lower-cost, biosimilar versions are included on health plan formularies.

(RTTNews) - Sandoz, the generics and biosimilars division of Swiss drug major Novartis AG (NVS), said Monday that the European Commission granted marketing authorization in the European Union for a ...